SUPPORT INFORMATION DURING COVID-19

At Janssen, we feel our first responsibility is to patients, doctors and nurses, and all others who use our products and services. We are expanding support to our communities and healthcare workers on the front lines of this crisis, progressing the development of a vaccine and the identification of potential treatments for COVID-19, as well as taking measures to ensure our patients and healthcare professionals have access to the Johnson & Johnson medicines, devices, and consumer products they depend on.

During these uncertain times of the COVID-19 pandemic, Janssen continues to be a partner for you in the care of your patients. We understand you may have questions about our product support and safety information. We are committed to providing you with the necessary information you need in a timely manner to support your efforts.

In light of the economic challenges of COVID-19, we would like to remind you about access and affordability information for patients prescribed Janssen medicines, including patients who have lost their health insurance. We want this information to be used for patients starting Janssen medicines or continuing therapy in the current environment. As a reminder:

Janssen CarePath continues to offer programs supporting patients with different needs:

  • For eligible commercially insured patients starting or continuing on certain Janssen medicines, programs that help patients lower their out-of-pocket costs
  • For patients who have lost their jobs and insurance coverage, Janssen CarePath can provide a referral to independent foundations that offer free medicines
  • For new patients starting on most Janssen medicines, free trial product programs

As always, Janssen CarePath Care Coordinators can answer questions about insurance and out-of-pocket costs, as well as help locate sites of care for certain medicines.

Janssen CarePath remains fully prepared to meet additional patient needs brought on by the current economic situation and is the first place patients should go to learn about their options for support.

To learn more, you or your patients can visit JanssenCarePath.com or call 877-CarePath (877-227-3728), Monday through Friday, 8 AM to 8 PM ET.

Janssen Support AND RESOURCES DURING COVID-19:

Additional Information From U.S. Government, MEDICAL Societies, and PATIENT SUPPORT Organizations:

Janssen has not studied the use of STELARA® (ustekinumab) in patients with COVID-19 nor in patients at risk of contracting COVID-19. Starting and continuing treatment with STELARA® is at the discretion of healthcare professionals and the risks and benefits for each patient should be taken into consideration.

Please see the full Prescribing Information for additional information.